|
시장보고서
상품코드
2076268
간질환 치료제 시장 : 치료법별, 유통 채널별, 지역별Liver Diseases Therapeutics Market, Therapy Type, By Distribution Channel, and By Region |
||||||
간질환 치료제 시장은 2026년에 225억 5,000만 달러 규모에 달할 것으로 추정되며, 2033년까지 439억 4,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 10.0%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 225억 5,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 10.00% | 2033년 시장 규모 예측: | 439억 4,000만 달러 |
간은 인체에서 가장 큰 장기입니다. 음식의 소화, 에너지 저장, 독소 배출에 도움이 됩니다. 간 질환에는 A형 간염, B형 간염, C형 간염 등 바이러스에 의한 질환을 비롯해, 약물, 독소, 또는 과도한 알코올 섭취로 인해 발생하는 질환 등 다양한 종류가 있습니다. 그 예로는 지방간이나 간경변 등이 있습니다. 간암도 증가 추세를 보이는 질환 중 하나입니다. 혈색소침착증이나 윌슨병 등, 간에 영향을 미치는 유전성 질환도 몇 가지 있습니다. 간에 영향을 미치는 질환의 일반적인 증상으로는 복부나 다리의 부종, 멍이 잘 드는 것, 황달, 대변이나 소변의 색 변화 등이 있습니다. 영상 검사나 간 기능 검사를 통해 간 손상을 확인하고, 간 질환을 진단할 수 있습니다. 간 질환의 치료법으로는 거부반응 억제제/면역억제제, 항암제, 분자 표적 치료제, 백신, 항바이러스제, 면역글로불린, 코르티코스테로이드 등이 있습니다.
시장 역학
간 질환 유병률의 증가, 신약 연구 개발, 그리고 간질환 치료제에 대한 규제 당국의 승인이 전 세계 간질환 치료제 시장의 성장 요인으로 작용하고 있습니다. 예를 들어, 2022년 5월 26일, 미국에 본사를 둔 제약사 화이자는 간섬유증을 동반한 비알코올성 지방간염(NASH) 치료를 목적으로 진행 중인 자사의 병용요법에 대해 미국 식품의약국(FDA)으로부터 패스트트랙 지정을 받았다고 발표했습니다. '패스트 트랙'는 중증 질환의 치료 및 예방을 목적으로, 미충족 의료 수요에 대응하는 신약 및 백신의 개발을 촉진하고 심사를 신속히 진행하기 위해 마련된 제도입니다. 이 병용요법에 사용되는 두 가지 약물은 엘보가스타트와 크레사코스타트입니다. 이번 결정은 화이자사의 비임상시험 및 2a상 임상시험 결과를 바탕으로 내려진 것으로, 해당 약물은 간 내 지방이 감소하는 것으로 나타났으며, 우수한 안전성 및 내약성 프로파일이 확인되었습니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하고 있는 경쟁 전략에 관한 중요한 인사이트도 제공하고 있습니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 간질환 치료제 시장의 주요 기업 개요을 소개하고 있습니다.
- 본 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 본 '세계 간질환 치료제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 간질환 치료제 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 간질환 치료제 시장 : 요법 유형별, 2021-2033년
제5장 세계의 간질환 치료제 시장 : 유통 채널별, 2021-2033년
제6장 세계의 간질환 치료제 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSM 26.07.07Liver Diseases Therapeutics Market is estimated to be valued at USD 22.55 Bn in 2026 and is expected to reach USD 43.94 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.0% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 22.55 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.00% | 2033 Value Projection: | USD 43.94 Bn |
Liver is the largest organ of the human body. It helps to digest food, store energy, and remove poisons. There are many kinds of liver diseases like diseases caused by viruses such as hepatitis A, hepatitis B, and hepatitis C. Diseases can also be caused by drugs, poisons, or too much alcohol consumption. Examples include fatty liver disease and cirrhosis. Live cancer is another growing disease. There are several inherited disorders like hemochromatosis and Wilson disease that affect the liver. The common symptoms of diseases affecting the liver include swelling of the abdomen and legs, bruising easily, Jaundice, and change in color of stool and urine. Imaging tests and liver function tests can check liver damage and diagnose liver disease. Treatments given for liver diseases include anti-rejection drugs/immunosuppressants, chemotherapy drugs, targeted therapy, vaccines, anti-viral drugs, immunoglobulins, and corticosteroids.
Market Dynamics
Increasing prevalence of liver diseases, research and development of novel therapeutics, and approvals from regulatory bodies for liver disease treatment are attributed to the growth of the global liver diseases therapeutics market. For instance, on May 26, 2022, Pfizer Inc., U.S. based pharmaceutical company announced U.S. Food and Drug Administration granted fast-track designation to Pfizer's investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. Fast Track is a process designed to facilitate the development and expedite the review of new drugs and vaccines intended to treat or prevent serious conditions and address unmet medical needs. The two drugs in combinational therapies are ervogastat and clesacostat. The decision was made based on Pfizer's nonclinical studies and phase 2a clinical study of drugs which showed reduced liver fat with favorable safety and tolerability profile.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global liver diseases therapeutics market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc..
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global liver diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global liver diseases therapeutics market.
Detailed Segmentation:
- Global Liver Diseases Therapeutics Market, Therapy Type:
- Anti-Rejection Drugs/Immunosuppressant
- Chemotherapy Drugs
- Targeted therapy
- Vaccines
- Anti-Viral Drugs
- Immunoglobulin's
- Corticosteroids
- Global Liver Diseases Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles
- Astellas Pharma Inc. *
- Bristol-Myers Squibb
- Gilead Sciences
- Glaxosmithkline Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Sanofi S.A
- Pfizer Inc.
- Takeda Pharmaceutical
- Valeant Pharmaceuticals
- Watson Pharmaceuticals, Inc.
- Theratechnologies Inc.
- Alnylam Pharmaceuticals, Inc.
- Protagonist Therapeutics, Inc.
- Dicerna Pharmaceuticals, Inc.
- Endo International
- Provectus Biopharmaceuticals Inc.
- MAX BioPharma, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Therapy Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Liver Diseases Therapeutics Market, By Therapy Type, 2021-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Anti-Rejection Drugs/Immunosupressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Chemotherapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Targeted therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Anti-Viral Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Immunoglobulins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
5. Global Liver Diseases Therapeutics Market, By Distribution Channel, 2021-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
6. Global Liver Diseases Therapeutics Market, By Region, 2021-2033, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Billion)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol-Myers Squibb.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Glaxosmithkline Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi S.A
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Takeda Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Valeant Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Watson Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Theratechnologies Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Alnylam Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Protagonist Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Dicerna Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Endo International
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Provectus Biopharmaceuticals Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- MAX BioPharma, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
8. Section
- Research Methodology
- About Us
